Acacia Research Corp., of Newport Beach, Calif., said its CombiMatrix group and the Biodesign Institute at Arizona State University are collaborating on the development of a peptide array synthesizer using CombiMatrix's virtual-flask technology. Biodesign Institute's Center for BioOptical Nanotechnology is purchasing CombiMatrix equipment and funding development of the synthesizer. The parties would share revenue.

Bolder BioTechnology Inc., of Wheat Ridge, Colo., was awarded a $121,844 Phase I Small Business Innovation Research grant from the National Cancer Institute. The grant provides funds to evaluate the effectiveness of the company's long-acting gamma interferon analogue to treat ovarian cancer in animal models.

Cel-Sci Corp., of Vienna, Va., said the American Stock Exchange accepted the company's plan to bring itself into compliance with listing standards. Cel-Sci, which fell out of AMEX guide compliance with shareholder's equity of less than $4 million and losses from continuing operations and/or net losses in three out of four of its most recent fiscal years, was granted an extension to Dec. 31, 2006, to regain compliance.

CV Therapeutics Inc., of Palo Alto, Calif., said it issued new inducement stock options to 44 nonexecutive employees due to additional hiring, primarily in connection with its commercialization efforts to co-promote Aceon (perindopril erbumine) tablets in the U.S. The options cover 146,000 shares of common stock and are classified as non-qualified stock options with an exercise price equal to the fair market value on the grant date.

Epimmune Inc., of San Diego, said its stockholders approved the merger with Paris-based Immuno-Designed Molecules SA, and the common stock of the combined company will be listed on the Nasdaq National Market under the ticker symbol "IDMI." The merger gives Epimmune a more advanced clinical pipeline, a stronger balance sheet and significant corporate partnerships, said its president and CEO, Emile Loria. The merger was announced in March. (See BioWorld Today, March 17, 2005.)

Galapagos NV, of Mechelen, Belgium, and High Q Foundation Inc., of New York, reached agreement in principle for a two-year alliance to apply Galapagos' adenoviral Silence Select siRNA collection and FleXSelect cDNA collection to discover drug targets for Huntington's disease. Galadeno, Galapagos' partnering unit, would perform the research, and Galapagos would receive up to $3 million from High Q, as well as retain the option to further develop certain targets identified during the collaboration. A final agreement is expected to be signed by Oct. 1.

Genomic Profiling Systems Inc., of Bedford, Mass., said it would receive a three-year $4.1 million Phase II Small Business Innovation Research grant from the National Institute of Allergy and Infectious Disease to develop a "surge" testing platform for the diagnosis of anthrax. The MultiPath system will enable emergency testing on a mass scale.

Myogen Inc., of Denver, said results from a Phase II trial of ambrisentan demonstrated efficacy and safety results at four doses in patients with pulmonary arterial hypertension. After 12 weeks of treatment, ambrisentan increased 6-minute walk distance by 36.1 meters, and improvements also were observed in the Borg dyspnea index, WHO functional class, subject global assessment, mean pulmonary arterial pressure and cardiac index. The data were published in the August 2005 issue of the Journal of the American College of Cardiology. Ambrisentan is an oral endothelin type A receptor-selective antagonist.

Spherics Inc., of Lincoln, R.I., said it is relocating its headquarters and research operations to Mansfield, Mass., where it plans to build a clinical scale manufacturing facility. In connection with the move, Spherics will receive a $2.5 million loan from MassDevelopment's Emerging Technology Fund. Spherics is developing oral pharmaceutical products with improved therapeutic profiles by applying its drug delivery platform technologies.

Tissera Inc., of Herzlia, Israel, said its sponsored research team at the Weizmann Institute of Science showed extensive proliferation of hepatic cells after pig fetal liver fragments transplantation, without any preparative manipulation of the host liver. Previous studies have shown that proliferation of transplanted isolated hepatocytes can be achieved only in conjunction with destructive manipulations of host liver.

No Comments